PHILADELPHIA ? July 5, 2007 ? The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug?s developer, OSI Pharmaceuticals, Inc.
From: www.cancerfacts.com
Rash from newer drugs linked to longer survival
Posted by Ruslan Abuzant at 1:20 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment